Ask AI
ProCE Banner Series

Optimizing Outcomes With Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Best Practices for Oncology Pharmacists

Explore emerging strategies for smoldering multiple myeloma and newly diagnosed multiple myeloma, including risk assessment, treatment selection, and the evolving role of anti-CD38–based regimens in frontline care. For practical, evidence-based insights on personalizing therapy and supportive care, register now.

  ACPE-P
Who Should Attend

This activity has been designed to meet the educational needs of oncology pharmacists and other healthcare professionals caring for patients with high-risk smoldering or newly diagnosed multiple myeloma.

All Events

Optimizing Outcomes With Anti-CD38–Based Treatment for Smoldering and Newly Diagnosed Multiple Myeloma: Best Practices for Oncology Pharmacists

Upcoming Events

May

13

2026

6:00 PM - 7:00 PM Eastern Time (ET)

Virtual

June

15

2026

5:00 PM - 6:00 PM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ knowledge, confidence, and competence at optimizing management of patients with high-risk smoldering or newly diagnosed multiple myeloma who are eligible for anti-CD38–based treatment.

Target Audience
This activity has been designed to meet the educational needs of oncology pharmacists and other healthcare professionals caring for patients with high-risk smoldering or newly diagnosed multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Educate patients with high-risk smoldering MM on the latest evidence and expert guidance on anti-CD38–based treatment to support informed shared decision-making

  • Recommend individualized treatment strategies leveraging anti-CD38–based quadruplets for appropriate patients with newly diagnosed symptomatic MM based on the latest clinical evidence, expert recommendations, and patient/disease factors

  • Apply pharmacist-led strategies to mitigate and manage adverse events related to anti-CD38–based treatments for MM

Accreditation

Pharmacists

ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-26-003-L01-P has been assigned to this live application-based activity (initial release date May 13, 2026). This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.deceraclinical.com/education, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure of Conflicts of Interest
ProCE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by ProCE, LLC

ProCE, LLC

Supporters

Supported by educational grants from Johnson & Johnson and Sanofi Genzyme.

Johnson & Johnson

Sanofi Genzyme

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191